This study is for patient that have been diagnosed with High Risk Neuroblastoma. The investigational drug in this study is naxitamab. The purpose of this study is to test the safety of adding an Anti-GD2 Immunotherapy agent (naxitamab) to your standard therapy during the induction phase of care. Read the sections on risks and benefits carefully and be sure you understand them. This study will also look at the effectiveness of this treatment.

This study is for patients that have been diagnosed with high risk neuroblastoma. This study is testing an investigational drug called Dinutuximab, which will be combined with standard care induction and transplant. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA).
The primary purpose of this study is to compare treatment outcomes of participants who are assigned to early chemoimmunotherapy (Dinutuximab and Sargramostim) during Induction to treatment outcomes of participants who are not assigned to treatment that includes early chemoimmunotherapy. Participants will be randomized to the standard of care arm of the trial or the standard of care arm plus chemoimmunotherapy (like flipping a coin). The investigational drug is given to participants through IV infusion. Participants in this study can expect to be in this study for a total of five years.

This study is recruiting pediatric patients who have been diagnosed with rhabdomyosarcoma (RMS). RMS is a type of cancer that occurs in the soft tissues of the body. The goal of the study is to compare the effects, good and/or bad, of giving less chemotherapy drugs to people with very low risk-RMS to find out which is better. Patients will be separated into two groups based on their tumor type: Low Risk and Very Low Risk. Participants in the Low Risk group will receive Vincristine, Dactinomycin and Cyclophosphamide. Participants in the Low Risk group will receive Vincristine and Dactinomycin. All participants will be tested for genetic differences (called MYOD1 and TP53). If any participant is found to have these genetic differences, they will receive Vincristine, Dactinomycin and Cyclophosphamide. Common side effects of chemotherapy include nausea, vomiting, hair loss, and fatigue (tiredness). Participants will receive the medications through an IV in their arm. Study participation is expected to last up to one year.

This study is recruiting pediatric patients who have been diagnosed with osteosarcoma. Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. The goal of the study is to determine the feasibility of adding cabozantinib to standard MAP (high dose methotrexate, doxorubicin, and cisplatin) chemotherapy in patients with newly diagnosed metastatic osteosarcoma with a resectable primary tumor and to compare the effects, good and/or bad, of cabozantinib in combination with MAP versus MAP alone on people with newly diagnosed OST to find out which is better. Common side effects of chemotherapy include nausea, vomiting, hair loss, and fatigue (tiredness). Participants will receive the medications through an IV in their arm and PO. Study participation is expected to last up to 16 months.